VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Receives Average Rating of “Reduce” from Analysts

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) have been given a consensus rating of “Reduce” by the five research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $0.95.

Several analysts have commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen lowered shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st.

VistaGen Therapeutics Stock Performance

VTGN stock opened at $0.61 on Tuesday. The firm has a market cap of $24.12 million, a price-to-earnings ratio of -0.32 and a beta of 0.33. The firm has a 50-day simple moving average of $0.59 and a two-hundred day simple moving average of $1.95. VistaGen Therapeutics has a one year low of $0.43 and a one year high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings results on Thursday, February 12th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.06. The firm had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.14 million. As a group, equities analysts predict that VistaGen Therapeutics will post -1.88 earnings per share for the current fiscal year.

Hedge Funds Weigh In On VistaGen Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of VTGN. Luminus Management LLC purchased a new position in shares of VistaGen Therapeutics in the 4th quarter valued at approximately $232,000. Two Sigma Investments LP raised its position in shares of VistaGen Therapeutics by 223.5% in the 3rd quarter. Two Sigma Investments LP now owns 289,409 shares of the company’s stock valued at $1,027,000 after purchasing an additional 199,958 shares during the last quarter. Millennium Management LLC raised its position in shares of VistaGen Therapeutics by 853.0% in the 4th quarter. Millennium Management LLC now owns 197,045 shares of the company’s stock valued at $130,000 after purchasing an additional 176,369 shares during the last quarter. OMERS ADMINISTRATION Corp purchased a new position in shares of VistaGen Therapeutics in the 4th quarter valued at approximately $68,000. Finally, Jane Street Group LLC purchased a new position in shares of VistaGen Therapeutics in the 2nd quarter valued at approximately $190,000. 78.39% of the stock is owned by hedge funds and other institutional investors.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.